Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Gaucher Disease Type 1 Clinical Trial

Official title:
Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease

Status Completed

Clinical Trial Summary

Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00319046
Study type	Interventional
Source	Actelion
Contact
Status	Completed
Phase	Phase 3
Start date	February 1, 2006
Completion date	July 1, 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02583672` - Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)	Phase 2
Recruiting	`NCT04055831` - Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease
Withdrawn	`NCT02528617` - The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease	Phase 4
Active, not recruiting	`NCT02843035` - Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	Phase 2
Completed	`NCT02067247` - Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease	N/A
Completed	`NCT06050967` - A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.	Phase 2